Nanotherapeutics Acquires Late Stage Clinical Program for Alzheimer's Treatment

December 16, 2009 - Nanotherapeutics, Inc., a privately held biopharmaceutical company, announced that it has acquired in bankruptcy proceedings two late stage clinical programs: Ramoplanin from Oscient Pharmaceuticals Corporation and PRX-3140 from EPIX Pharmaceuticals, Inc. Ramoplanin - an oral antibiotic for the treatment of Clostridium difficileassociated disease (CDAD) - is entering Phase 3 trials. PRX-3140 - an orally-bioavailable Alzheimer’s treatment - is in Phase 2 clinical studies. Nanotherapeutics also acquired the U.S. and foreign patent estates covering each clinical program... [PDF] Nanotherapeutics' Press Release -

Proteostasis Therapeutics: Paper in Cell Establishing Role of the Proteostasis Network in Alzheimer's Disease

December 15, 2009 - Proteostasis Therapeutics announced that modulating a key Proteostasis Network (PN) pathway may offer a novel approach to Alzheimer’s disease, a finding that was published in the journal Cell by its scientific founders Andrew Dillin, Ph.D., and Jeffery Kelly, Ph.D. The publication describes how regulation of an aggregase pathway reduced the neurodegenerative effects of beta amyloid aggregates that are a hallmark of the disease. Proteostasis has exclusively licensed the intellectual property for modulating this pathway from the Salk Institute and is integrating it into its proprietary technology platform directed to the discovery of a new class of therapeutics, Proteostasis Regulators (PR), small molecules designed to correct defects in the PN... Proteostasis Therapeutics' Press Release -

Neurotez : "Testing a Leptin product as a novel therapy for Alzheimer's disease"

Oct. 14 2009 - Neurotez : Dr. J. Wesson Ashford, MD, PhD (Clinical Professor at Stanford University and a Senior Scientist at the Palo Alto VA) will be presenting at the the CTAD (Clinical Trials in Alzheimer's disease) meeting in Las Vegas on Oct 30th, 2009. The title of his talk is: "Testing a Leptin product as a novel therapy for Alzheimer's disease". Neurotez's news -